Powering Health from within
MitoGenix Therapeutics
While generalized genomics platforms overlook the complex metabolic signals of mitochondrial DNA, our specialized infrastructure turns these scarce insights into a distinct competitive advantage.
Beyond our core discovery pipeline, we leverage our proprietary predictive models to pioneer a breakthrough prehospital triage platform, delivering deep-score clinical outcome predictions for traumatic brain injury (TBI) and PTSD.
By uniting wet-lab precision, advanced bioinformatics, and frontline clinical diagnostics under a single architecture, we own the entire mitochondrial data pipeline from initial sequence to bedside intervention.
We are a vertically integrated mitochondrial genetics platform, systematically cutting drug development timelines by 50% by eliminating the fragmented vendor chain.
Through our strategic partnership with Azenta (GeneWiz), we seamlessly ingest everything from raw sequencing counts to disparate external datasets into a centralized, machine-learning-driven analytics engine.
By combining this predictive AI with our own genetically modified mitochondrial cell lines and full-service experimental handoffs, we offer biopharma clients a continuous loop of target discovery, validation, and virtual transfer workflows—all executed at a fraction of traditional CRO or academic costs.
Mission: To accelerate mitochondrial genetic therapeutic research by providing researchers with high-quality, pre-engineered genetically modified mitochondria in human and murine cell lines paired with robust in vitro models for mitochondrial transfer and reprogramming fused with our proprietary machine learning platform that allows accurate prediction for mitochondrial genetics analysis and accelerate target discovery while advancing clinical applications while saving time, reducing effort, and enhancing efficiency.
Vision: To be the global leader in providing innovative and reliable tools for mitochondrial research, enabling breakthroughs in understanding and treating mitochondrial diseases and age-related disorders.
Values: Innovation, collaboration, integrity, accountability, and respect
Mitigate R&D Bottlenecks for Mitochondrial Therapies
We provide robust, pre-validated mitochondrial transfer models and datasets, delivering a documented 40–60% reduction in model development time and accelerating your pipeline progression to IND
Validated, Ready-to-Use Systems
Access proprietary, off-the-shelf, genetically modified mitochondria and optimized cell lines, bypassing months of preliminary validation work required for novel mitochondrial reprogramming studies.
Unlocking Cellular Reprogramming via Patented Mitochondria Transfer
Gain exclusive access to patent-pending datasets and validated tools focused on the direct transfer of healthy mitochondria, providing a unique, disease-modifying strategy unavailable through standard genetic approaches
Data-Driven Predictive Power via ML
Leverage our cutting-edge ML platform, which is continually trained by client data, to generate highly accurate predictions of mitochondrial genetic transfer efficacy and subsequent cell reprogramming outcomes, maximizing research success rates.
Strategic Focus on High-Impact Therapeutic Areas
Our tools provide novel mechanistic solutions for complex chronic diseases, including Neurodegeneration, Metabolic Disorders, Oncology, and critical Military Health applications, ensuring broad relevance across your research portfolio
Regulatory Advantage in Rare and Orphan Disease
Our systems are specifically designed to generate data supporting clinical development in areas (including orphan/rare diseases) that qualify for expedited regulatory pathways, helping to de-risk and accelerate your time to market
Our Team
Roberto Ivan Mota Alvidrez, MD, MS, FAHA
rmotaalvidrez@mitogenixtherapeuticsllc.com
Itzel Nahomi Perez Reyes, MD
inperez@mitogenixtherapeuticsllc.com
Join Our Team
〰️
Join Our Team 〰️
Our Goal
50% reduction in model development time
Validated, Ready-to-Use Systems for Advancing Research Discovery and Target Validation
Proprietary & Deep Predictive-Mechanistic Insight
Broad Application & Strategic De-Risking
ML platform enhances hypothesis generation and experimental validation, easy to use from a high school student all the way to a CRO, PI or senior postdoc
Accelerating timelines to IND; De-risking novel drug targets, particularly in complex/orphan diseases; Seeking mechanisms (like mitochondrial transfer) with high therapeutic potential
Our Services
-
Upcoming service. Our flagship offering will consists of human and murine cell lines containing genetically modified mitochondria for RNA and DNA genetic pathway analysis and reprogramming prediction.
-
Upcoming Service. Developed and validated robust in vitro models that simulate and facilitate mitochondrial transfer
-
Upcoming Service. Specialized assays to assess the functional impact of transferred mitochondria on recipient cell metabolism, gene expression, and phenotype
-
Upcoming Service. Tailored genetic modifications to mitochondria based on specific client research requirements
-
Upcoming Service. Proprietary cutting-edge ML platform, which is continually trained by client data, to generate highly accurate predictions of mitochondrial genetic transfer efficacy and subsequent cell reprogramming outcomes, maximizing research success rates.
-
Experienced expert who provides strategic advice, analyzes company data, and drives project outcomes, providing strategic solutions to companies and addressing their business needs.
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!
Featured Partners
